Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

NCT01990846

Influenza

COMPLETED PHASE1

Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

NCT05507567

Influenza Viral Infections

COMPLETED PHASE2

Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

NCT06613737

Influenza A H3N2

COMPLETED NA

Influenza Vaccine Challenge Study in Healthy Subjects

NCT01226758

Influenza

COMPLETED PHASE1

Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects

NCT00947687

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FF-3 dry powder

FF-3

Group Type EXPERIMENTAL

FF-3 dry powder

Intervention Type DRUG

FF-3 dry powder administered by nasal inhalation

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo dry powder administered by nasal inhalation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FF-3 dry powder

FF-3 dry powder administered by nasal inhalation

Intervention Type DRUG

Placebo

Placebo dry powder administered by nasal inhalation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male and non-pregnant, non-lactating female subjects of 18 to 50 years of age inclusive
2. Body Mass Index (BMI) of 18 to 32 kg/m2 inclusive and body weight of 50 to 110 kg inclusive.
3. Normal spirometry values at Screening and Baseline
4. Post-menopausal women with amenorrhea for at least 2 years will be eligible
5. Females of childbearing potential must use two acceptable birth control methods throughout the study and for 30 days after the last dose of the IMP:
6. Male subjects:

* Must agree to use a condom (or diaphragm) plus spermicide in female partner) from the time of the first dose of IMP through 90 days after the last dose.
* Must agree to not donate sperm for 90 days after the last dose of IMP.
* Documented evidence of vasectomies in males for 180 days minimum prior to the first dose of the IMP is an acceptable form of contraception.
* Males who claim abstinence as their method of contraception are allowed provided they agree to use a double barrier method (diaphragm plus spermicide in female partner or condom) should they become sexually active from screening to 90 days after the last dose of IMP.
7. Willing and able to provide written informed consent.
8. Willing and able to adhere to the lifestyle guideline restrictions outlined in the protocol

Exclusion Criteria

1. Evidence of or history of clinically significant oncologic, pulmonary, hepatic, gastrointestinal, cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic, endocrine , or psychiatric disease.
2. Current infection of any nature unless agreed as insignificant to the study by the Investigator and Medical Monitor.
3. Nasal abnormalities, including nasal septum deviation, septum perforations, or polyps; history of recurrent epistaxis; history of sinus surgery and/or persistent hypertrophic inferior turbinates.
4. Significant abnormalities at screening in safety laboratory tests, ECGs, or spirometry.
5. Broncho-reactive airway disease (asthma, chronic obstructive pulmonary disease, current allergic rhinitis, cystic fibrosis, chronic bronchitis, emphysema). Individuals with a history of childhood asthma are not necessarily excluded and acceptable for screening.
6. History of significant nasal irritation from use of nasal sprays or drops.
7. History of drug or alcohol abuse within the past 2 years
8. Nicotine product users
9. Received an investigational drug or participated in another research study within 90 days of the first dose of IMP.
10. Participated in a previous investigational study of FF-3.
11. History of influenza vaccination with a live or attenuated vaccine within the previous year
12. Use of prescription drugs within 14 days prior to the first dose of IMP, excepting oral contraceptives.
13. Received any non-prescription medications, vitamins, or dietary supplements within 14 days of administration of the first dose of IMP, unless both the Principal Investigator and the Medical Monitor grant prior approval. Herbal supplements must be discontinued 7 days prior to the first dose of IMP.

15\. Tested positive for alcohol at screening or admission to the CRU. 16. Positive urine pregnancy test at the Screening Visit or positive serum pregnancy test on admission to the CRU (females only).

17\. Positive test for HIV, hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (anti-HCV) at the screening visit.

18\. Positive urine drug test at the screening visit or at admission to the CRU. 19. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.

20\. Subjects who have donated blood or experienced other significant blood loss within 56 days of screening for the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes